Basic Information
| RNALocate ID: | RLID:11001550 |
| RNA Symbol: | hsa-miR-222-3p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-222-3p |
| RNA ID: | miRBase:MIMAT0000279 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23077538 |
| Tissue/Cell Line: | Plasma |
| Method: | Solexa sequencing |
| Description: | To characterize the stability of secreted miRNAs in plasma, we selected eight plasma miRNAs with relatively high copy numbers detected by Solexa sequencing (Table S1).Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001674 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001675 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001676 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001677 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001678 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001679 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11001538 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
| RLID:11001539 | Exosome | Human cervical cancer cell line (HeLa) | 25760330 |
| RLID:11001540 | Exosome | Gemcitabine-resistant cell line (A549-GR)|Gemcitabine-sensitive A549 parental cells (A549-P) | 28743280 |
| RLID:11001541 | Exosome | Plasma | 30458449 |
| RLID:11001542 | Exosome | BC cell lines (HCC70|MCF-7|MDA-MB-231) | 30728048 |
| RLID:11001543 | Exosome | Peripheral blood mononuclear cells | 19002258 |
| RLID:11001544 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11001545 | Exosome | Renal cancer cells | 21670082 |
| RLID:11001546 | Exosome | Brain tissue | 23382797 |
| RLID:11001547 | Exosome | Plasma | 23663360 |
| RLID:11001548 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11001549 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11001551 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11001552 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000064 | Exosome | Blood|B lymphoblastoid cells|Breast tissue|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Mast cells|Tongue tissue | |
| RLID-D:11000338 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-222-3p | Diffuse large b cell lymphoma | MNDR-E-MI-30845 |
| MNDR | hsa-miR-222-3p | Splenic marginal zone lymphoma | MNDR-E-MI-30846 |
| MNDR | hsa-miR-222-3p | Colorectal adenoma | MNDR-E-MI-30847 |
| MNDR | hsa-miR-222-3p | Oral tongue squamous cell carcinoma | MNDR-E-MI-30848 |
| MNDR | hsa-miR-222-3p | Oral squamous cell carcinoma | MNDR-E-MI-30849 |
| MNDR | hsa-miR-222-3p | Medulloblastoma | MNDR-E-MI-30850 |
| MNDR | hsa-miR-222-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-30851 |
| MNDR | hsa-miR-222-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-30852 |
| MNDR | hsa-miR-222-3p | Lymphoma | MNDR-E-MI-30853 |
| MNDR | hsa-miR-222-3p | Lymphoma non-hodgkin | MNDR-E-MI-30854 |
| MNDR | hsa-miR-222-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-30855 |
| MNDR | hsa-miR-222-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-30856 |
| MNDR | hsa-miR-222-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-30857 |
| MNDR | hsa-miR-222-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-30858 |
| MNDR | hsa-miR-222-3p | Her2-receptor positive breast cancer | MNDR-E-MI-30859 |
| MNDR | hsa-miR-222-3p | Breast cancer luminal | MNDR-E-MI-30860 |
| MNDR | hsa-miR-222-3p | Niemann-pick disease type c | MNDR-E-MI-30861 |
| MNDR | hsa-miR-222-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-30862 |
| MNDR | hsa-miR-222-3p | Colorectal carcinoma | MNDR-E-MI-30863 |
| MNDR | hsa-miR-222-3p | Dermatomyositis | MNDR-E-MI-30864 |
| MNDR | hsa-miR-222-3p | Prostate cancer | MNDR-E-MI-30865 |
| MNDR | hsa-miR-222-3p | Prostate carcinoma | MNDR-E-MI-30866 |
| MNDR | hsa-miR-222-3p | Chronic lymphocytic leukemia | MNDR-E-MI-30867 |
| MNDR | hsa-miR-222-3p | Gastric cancer | MNDR-E-MI-30868 |
| MNDR | hsa-miR-222-3p | Gastric lymphoma | MNDR-E-MI-30869 |
| MNDR | hsa-miR-222-3p | Alzheimer disease | MNDR-E-MI-30870 |
| MNDR | hsa-miR-222-3p | Intracranial aneurysm | MNDR-E-MI-30871 |
| MNDR | hsa-miR-222-3p | Urinary bladder cancer | MNDR-E-MI-30872 |
| MNDR | hsa-miR-222-3p | Dysautonomia familial | MNDR-E-MI-30873 |
| MNDR | hsa-miR-222-3p | Polycystic ovary syndrome | MNDR-E-MI-30874 |
| MNDR | hsa-miR-222-3p | Duchenne muscular dystrophy | MNDR-E-MI-30875 |
| MNDR | hsa-miR-222-3p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-30876 |
| MNDR | hsa-miR-222-3p | Leukemia | MNDR-E-MI-30877 |
| MNDR | hsa-miR-222-3p | Huntington disease | MNDR-E-MI-30878 |
| MNDR | hsa-miR-222-3p | Chorea | MNDR-E-MI-30879 |
| MNDR | hsa-miR-222-3p | Cardiovascular disease | MNDR-E-MI-30880 |
| MNDR | hsa-miR-222-3p | Carotid stenosis | MNDR-E-MI-30881 |
| MNDR | hsa-miR-222-3p | Lung cancer | MNDR-E-MI-30882 |
| MNDR | hsa-miR-222-3p | Endometrial cancer | MNDR-E-MI-30883 |
| MNDR | hsa-miR-222-3p | Down syndrome | MNDR-E-MI-30884 |
| MNDR | hsa-miR-222-3p | Parkinson disease | MNDR-E-MI-30885 |
| MNDR | hsa-miR-222-3p | Niemann-pick disease | MNDR-E-MI-30886 |
| MNDR | hsa-miR-222-3p | Colonic adenomas | MNDR-E-MI-30887 |
| MNDR | hsa-miR-222-3p | Breast cancer | MNDR-E-MI-30888 |
| MNDR | hsa-miR-222-3p | Thyroid cancer | MNDR-E-MI-30889 |
| MNDR | hsa-miR-222-3p | Pituitary neoplasms | MNDR-E-MI-30890 |
| MNDR | hsa-miR-222-3p | Pancreatic cancer | MNDR-E-MI-30891 |
| MNDR | hsa-miR-222-3p | Melanoma | MNDR-E-MI-30892 |
| MNDR | hsa-miR-222-3p | Atherosclerosis | MNDR-E-MI-30893 |
| MNDR | hsa-miR-222-3p | Nephroblastoma | MNDR-E-MI-30894 |
| MNDR | hsa-miR-222-3p | Colon cancer | MNDR-E-MI-30895 |
| MNDR | hsa-miR-222-3p | Ischemic attack transient | MNDR-E-MI-30896 |
| MNDR | hsa-miR-222-3p | Acromegaly | MNDR-E-MI-30897 |
| MNDR | hsa-miR-222-3p | Prostate adenocarcinoma | MNDR-E-MI-30898 |
| MNDR | hsa-miR-222-3p | Carcinoma ductal breast | MNDR-E-MI-30899 |
| MNDR | hsa-miR-222-3p | Glioblastoma | MNDR-E-MI-30900 |
| MNDR | hsa-miR-222-3p | Glioma | MNDR-E-MI-30901 |
| MNDR | hsa-miR-222-3p | Nemaline myopathy | MNDR-E-MI-30902 |
| MNDR | hsa-miR-222-3p | Chordoma | MNDR-E-MI-30903 |
| MNDR | hsa-miR-222-3p | Epilepsy temporal lobe | MNDR-E-MI-30904 |
| MNDR | hsa-miR-222-3p | Osteosarcoma | MNDR-E-MI-30905 |
| MNDR | hsa-miR-222-3p | Coronary artery disease | MNDR-E-MI-30906 |
| MNDR | hsa-miR-222-3p | Inclusion body myositis | MNDR-E-MI-30907 |
| MNDR | hsa-miR-222-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-30908 |
| MNDR | hsa-miR-222-3p | Meningioma | MNDR-E-MI-30909 |
| MNDR | hsa-miR-222-3p | Liver cancer | MNDR-E-MI-30910 |
| MNDR | hsa-miR-222-3p | Uterine cancer | MNDR-E-MI-30911 |
| MNDR | hsa-miR-222-3p | Cervical adenocarcinoma | MNDR-E-MI-30912 |
| MNDR | hsa-miR-222-3p | Gastric adenocarcinoma | MNDR-E-MI-30913 |
| MNDR | hsa-miR-222-3p | Pituitary adenoma | MNDR-E-MI-30914 |
| MNDR | hsa-miR-222-3p | Carcinoma lung non-small-cell | MNDR-E-MI-30915 |
| MNDR | hsa-miR-222-3p | Thyroid carcinoma | MNDR-E-MI-30916 |
| MNDR | hsa-miR-222-3p | Papillary thyroid carcinoma | MNDR-E-MI-30917 |
| MNDR | hsa-miR-222-3p | Ovarian carcinoma | MNDR-E-MI-30918 |
| MNDR | hsa-miR-222-3p | Pancreatic adenocarcinoma | MNDR-E-MI-30919 |
| MNDR | hsa-miR-222-3p | Liver disease | MNDR-E-MI-30920 |
| MNDR | hsa-miR-222-3p | Carcinoma renal cell | MNDR-E-MI-30921 |
| MNDR | hsa-miR-222-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-30922 |
| MNDR | hsa-miR-222-3p | Renal clear cell carcinoma | MNDR-E-MI-30923 |
| MNDR | hsa-miR-222-3p | Chromophobe renal cell carcinoma | MNDR-E-MI-30924 |
| MNDR | hsa-miR-222-3p | Biliary tract cancer | MNDR-E-MI-30925 |
| MNDR | hsa-miR-222-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-30926 |
| MNDR | hsa-miR-222-3p | Cholangiocarcinoma | MNDR-E-MI-30927 |
| MNDR | hsa-miR-222-3p | Pancreatitis | MNDR-E-MI-30928 |
| MNDR | hsa-miR-222-3p | Esophageal cancer | MNDR-E-MI-30929 |
| MNDR | hsa-miR-222-3p | Liver cirrhosis | MNDR-E-MI-30930 |
| MNDR | hsa-miR-222-3p | Oncocytoma | MNDR-E-MI-30931 |
| MNDR | hsa-miR-222-3p | Lung small cell carcinoma | MNDR-E-MI-30932 |
| MNDR | hsa-miR-222-3p | Gastric carcinoma | MNDR-E-MI-30933 |
| MNDR | hsa-miR-222-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-30934 |
| MNDR | hsa-miR-222-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-30935 |
| MNDR | hsa-miR-222-3p | Fibromyalgia | MNDR-E-MI-30936 |
| MNDR | hsa-miR-222-3p | Adenoma | MNDR-E-MI-30937 |
| MNDR | hsa-miR-222-3p | Breast invasive carcinoma | MNDR-E-MI-30938 |
| MNDR | hsa-miR-222-3p | Hepatocellular carcinoma | MNDR-E-MI-30939 |
| MNDR | hsa-miR-222-3p | Embryonal cancer | MNDR-E-MI-30940 |
| MNDR | hsa-miR-222-3p | B-cell lymphoma | MNDR-E-MI-30941 |
| MNDR | hsa-miR-222-3p | Rheumatoid arthritis | MNDR-E-MI-30942 |
| MNDR | hsa-miR-222-3p | T-cell leukemia | MNDR-E-MI-30943 |
| MNDR | hsa-miR-222-3p | Malignant pleural mesothelioma | MNDR-E-MI-30944 |
| MNDR | hsa-miR-222-3p | Retinoblastoma | MNDR-E-MI-30945 |
| MNDR | hsa-miR-222-3p | Neuroblastoma | MNDR-E-MI-30946 |
| MNDR | hsa-miR-222-3p | Burkitt lymphoma | MNDR-E-MI-30947 |
| MNDR | hsa-miR-222-3p | Oral cancer | MNDR-E-MI-30948 |
| MNDR | hsa-miR-222-3p | Neuromyelitis optica | MNDR-E-MI-30949 |
| MNDR | hsa-miR-222-3p | Psoriasis | MNDR-E-MI-30950 |
| MNDR | hsa-miR-222-3p | Skin cutaneous melanoma | MNDR-E-MI-30951 |
| MNDR | hsa-miR-222-3p | Skin melanoma | MNDR-E-MI-30952 |
| MNDR | hsa-miR-222-3p | Acute myelocytic leukemia | MNDR-E-MI-30953 |
| MNDR | hsa-miR-222-3p | Colorectal cancer | MNDR-E-MI-30954 |
| MNDR | hsa-miR-222-3p | Nasopharynx carcinoma | MNDR-E-MI-30955 |
| MNDR | hsa-miR-222-3p | Multiple myeloma | MNDR-E-MI-30956 |
| MNDR | hsa-miR-222-3p | Acute lymphocytic leukemia | MNDR-E-MI-30957 |
| MNDR | hsa-miR-222-3p | Ependymoma | MNDR-E-MI-30958 |
| MNDR | hsa-miR-222-3p | Cardiomegaly | MNDR-E-MI-30959 |
| MNDR | hsa-miR-222-3p | Nasopharyngeal cancer | MNDR-E-MI-30960 |
| MNDR | hsa-miR-222-3p | Prostatic neoplasms | MNDR-E-MI-30961 |
| MNDR | hsa-miR-222-3p | Sleep deprivation | MNDR-E-MI-30962 |
| MNDR | hsa-miR-222-3p | Polymyositis | MNDR-E-MI-30963 |
| MNDR | hsa-miR-222-3p | Epstein-barr virus infections | MNDR-E-MI-30964 |
| MNDR | hsa-miR-222-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-30965 |
| MNDR | hsa-miR-222-3p | Mptp poisoning | MNDR-E-MI-30966 |
| MNDR | hsa-miR-222-3p | Stroke lacunar | MNDR-E-MI-30967 |
| MNDR | hsa-miR-222-3p | Breast cancer her3+ negative | MNDR-E-MI-30968 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCG2 | Homo sapiens | RR00024743 |
TOP